Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines (MEXICHO)

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Danish Heart Foundation
Information provided by:
Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT00885651
First received: April 20, 2009
Last updated: April 21, 2009
Last verified: April 2009

April 20, 2009
April 21, 2009
September 2008
August 2009   (final data collection date for primary outcome measure)
Changes in stress-triggered response of catecholamines. [ Time Frame: 2 weeks and 3 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00885651 on ClinicalTrials.gov Archive Site
  • Change in stress-triggered blood pressure response. [ Time Frame: 2 weeks and 3 days ] [ Designated as safety issue: No ]
  • Change in stress-triggered pulse response. [ Time Frame: 2 weeks and 3 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines
A Randomised, Double Blinded, Crossover Study of the Influence of Metoprolol on Exercise Induced Elevation of Catecholamines in Healthy Subjects.

Heart failure is a frequent disease in Denmark, and it is associated with very high mortality. Around 60,000 people in Denmark have heart failure, and there is about 11,000 hospitalizations every year due to this disease. From the time of diagnosis, patients survive an average of 4-5 years.

A critical illness mechanism in heart failure is that these patients have high blood levels of catecholamines; epinephrine and norepinephrine, which is stress hormones from the sympathetic nervous system. Standard treatment of heart failure is with the two medical preparations betablockers and ACE-inhibitors.

It is not known what effect betablocker-treatment have on blood concentration of epinephrine and norepinephrine.

It is the purpose of this study, to investigate the effect of Selo-Zok ® (metoprolol) on the blood concentration of epinephrine and norepinephrine. This is done by creating a stress condition for the body, in this case with the bicycle test, while doing blood samples to determine the concentration of catecholamines. This will be done by 1-week treatment of tablet Selo-Zok ® followed by 1-week treatment of placebo (a substance with no medical effect). Blood samples will be taken to determine small changes in inheritance material (DNA) in the form of point mutations also called single nucleotide polymorphisms, since these changes can affect how we respond to metoprolol treatment.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Heart Failure
  • Drug: Metoprolole (Selo-Zok ®)
    Tablets, 200 mg, once a day, 10 days
  • Drug: Placebo
  • Experimental: 1
    Metoprolol for 10 days followed by placebo for 7 days.
    Interventions:
    • Drug: Metoprolole (Selo-Zok ®)
    • Drug: Placebo
  • Placebo Comparator: 2
    Placebo for 7 days followed by Metoprolol for 10 days
    Interventions:
    • Drug: Metoprolole (Selo-Zok ®)
    • Drug: Placebo
Petersen M, Andersen JT, Jimenez-Solem E, Broedbaek K, Hjelvang BR, Henriksen T, Frandsen E, Forman JL, Torp-Pedersen C, Køber L, Poulsen HE. Effect of the Arg389Gly β(1)-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment. Clin Exp Pharmacol Physiol. 2012 Sep;39(9):779-85. doi: 10.1111/j.1440-1681.2012.05736.x.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
30
December 2009
August 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Kaukaser
  • Healthy men
  • 18 years < age < 30 years
  • Non-smoker
  • 18 < BMI < 25
  • No chronic diseases
  • Motor-disability that disables completement of cardio-pulmonary exercise-test.

Exclusion Criteria:

  • Alcohol abuse or any other abuse
  • Intake of any narcotic drugs (example: cannabinoids, narcotics, stimulants of central nervous system, hypnotics, hallucinogenes)
  • Any of following medication:

    • astmamedication
    • heartmedication
    • antihistamines
    • antipsycotics
    • NSAIDs
    • rifampicine
    • chinidine
    • glucocorticoids
  • Abnormal ECG, particularly 2. or 3. degree AV-block, sinusbradycardia, sick sinusnode-syndrome, sign of heart failure or ischemia.
  • Allergy or intolerance of metoprolole
  • Lactoseallergy
  • 110 mmHg < Systolic blood pressure < 140 mmHg
  • 60 mmHg < Diastolic blood pressure < 90 mmHg
  • Bloodsucker > 11,1 mmol/L, or fasting, venous bloodsucker >= 7,0 (measured if: 7,8 < BS < 11,1)
Male
18 Years to 30 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00885651
13-5-23-9-3-8-15, EudraCTnr. 2008-001908-23
Yes
Morten Petersen, Department of Clinical Pharmacology, Rigshospitalet, Denmark
Rigshospitalet, Denmark
Danish Heart Foundation
Principal Investigator: Henrik HP Enghusen Poulsen, MD Rigshospitalet, Universityhospital of Copenhagen
Rigshospitalet, Denmark
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP